Gout in Black men: causes, the sudden attack, and long-term control

Gout is a type of inflammatory arthritis. It happens when urate, a waste product your body makes and your kidneys clear, builds up over years and forms needle-shaped crystals in and around a joint. When the immune system reacts to those crystals, the joint becomes intensely inflamed. That reaction is the attack. Gout is the most common inflammatory arthritis worldwide, and it is becoming more common (Dalbeth et al., Lancet 2021, PMID 33798500).

Several things raise your risk: being male, older age, family history, excess weight, high blood pressure, chronic kidney disease, and certain medications including diuretics (water pills) and low-dose aspirin (NIAMS, Gout).

Gout is more common in Black men than in white men. In a 2022 analysis of national survey data, age-standardized gout prevalence was 7.0 percent in Black men versus 5.4 percent in white men (McCormick et al., JAMA Network Open 2022, PMID 35969396). The gap in serious gout care is even wider. A nationwide study found Black Americans visited the emergency department for gout about 5 times as often, and were hospitalized for gout about 4 times as often, as white Americans (Yokose et al., Rheumatology 2022, PMID 36218483). That second gap is larger than the prevalence gap, which points at undertreatment: gout that should have been controlled with a daily pill instead landing people in the ER.

Here is the part that matters, because it is often told wrong. The higher prevalence in Black men was explained by differences in diet quality, chronic kidney disease, and diuretic use. After accounting for those factors, the racial difference disappeared (adjusted odds ratio 1.05). The authors concluded the disparity is largely attributable to differences in nongenetic social determinants of health rather than ancestry-specific differences in genes regulating urate handling. In plain terms: this is not a Black gene for gout. It is the downstream effect of high blood pressure, kidney disease, diuretics, and unequal access to the care that prevents flares.

A gout flare typically arrives fast, often in the middle of the night. The affected joint, most famously the big toe, becomes swollen, red, and warm, and the pain can be bad enough to wake you up. At its peak the joint is so tender that the weight of a bedsheet is unbearable (NIAMS, Gout; Dalbeth et al., Lancet 2021, PMID 33798500). The big toe is the classic site, but gout also strikes the midfoot, ankle, knee, and other joints.

Common triggers include alcohol, foods high in purines, sugar-sweetened drinks like soda, certain medications, dehydration, physical trauma, and other illnesses (NIAMS, Gout). A flare is not a sign you cheated. It is a sign there is enough urate in your body to keep forming crystals, which is the real problem to fix.

The goal during a flare is to shut down the inflammation quickly. The 2020 American College of Rheumatology guideline recommends one of three first-line options, used as appropriate to the patient: an NSAID (such as naproxen or indomethacin), colchicine, or a glucocorticoid (steroid) taken by mouth, injected into the joint, or given as a shot (FitzGerald et al., 2020 ACR Gout Guideline, PMC10563586). None of the three is universally best; the choice depends on your kidneys, your stomach, your blood pressure, your other medications, and what has worked before. Starting treatment early in the attack matters.

Two points specific to Black men, who carry more high blood pressure and kidney disease on average: NSAIDs can be hard on the kidneys and can push blood pressure up, and colchicine is dosed lower when kidney function is reduced. That is exactly why an attack is a doctor's-office (or telehealth) conversation, not a guessing game with leftover pills.

Treating the flare is firefighting. It does nothing about the urate still sitting in your body. The long-term fix is a daily medication that lowers blood urate until the crystals dissolve and stop forming. This is where gout is genuinely controllable, and it is the step most people never complete.

The 2020 ACR guideline (FitzGerald et al., PMC10563586) is direct about it:

• Who needs it. Daily urate-lowering therapy is strongly recommended for anyone with a tophus (a visible urate lump), joint damage on imaging from gout, or two or more flares a year.
• What to start. Allopurinol is the strongly preferred first-line drug for everyone, including people with moderate-to-severe kidney disease. This is important for Black men, because kidney disease is more common and allopurinol is still the right starting drug.
• How to start. Start low (allopurinol 100 mg/day or less, lower if you have kidney disease) and increase the dose over weeks to months.
• The target. Push the dose until your blood urate is under 6 mg/dL, then keep it there. This treat-to-target approach is what dissolves crystals and prevents future attacks.
• Bridge the start. When you begin urate-lowering therapy, urate levels shift and can briefly trigger more flares. The guideline recommends anti-inflammatory cover (low-dose colchicine, an NSAID, or a low-dose steroid) for at least 3 to 6 months while your body settles.

The single most common reason gout does not get better is that people start allopurinol, feel a flare in the first weeks, assume it failed, and quit. It did not fail. That early flare is expected, the bridge medication is designed for it, and the long game is what pays off.

If you have gout that lands you in the ER or that keeps coming back, that is the textbook signal you need daily urate-lowering therapy and a clinician tracking your urate level. You can find a provider through our directory, and our gout condition page walks through the full treatment path.

The most damaging myth about gout is that it is a diet disease you can fix at the dinner table. The evidence does not support that. A large 2018 BMJ analysis found that overall dietary patterns each explained 0.3 percent or less of the variation in blood-urate levels, while common genetic variation explained about 23.9 percent. The authors concluded that in contrast with genetic contributions, diet explains very little variation in serum urate levels in the general population (Major et al., BMJ 2018, PMID 30305269).

This does not mean food is irrelevant. Heavy alcohol, sugary drinks, and binges on purine-rich foods can trigger a flare in someone who already has gout. Cutting back is reasonable, and weight loss and treating blood pressure help your kidneys and heart for many reasons. But diet alone will not get most people's urate under 6 mg/dL, and being told to just eat better instead of being offered allopurinol is undertreatment. Food is a trigger to manage. Medication is the fix.

Gout rarely shows up alone. High blood pressure is present in a large share of people with gout, and chronic kidney disease of stage 3 or worse is common in this group as well (Dalbeth et al., Lancet 2021, PMID 33798500). The relationships run in both directions: high urate can strain the kidneys and blood vessels, and reduced kidney function lets urate build up. Diuretics prescribed for blood pressure also raise urate.

For Black men this cluster is the core of the gout story. High blood pressure and kidney disease are both more common, and they are exactly the factors that explained the higher gout rates in the first place. Controlling blood pressure, protecting the kidneys, and treating gout are not three separate projects. They are one. A clinician who sees the whole picture, rather than treating each flare as a one-off, is what changes the trajectory.